Hofseth Biocare Asa Stock Price To Sales
| HBC Stock | NOK 1.30 0.01 0.76% |
Hofseth Biocare ASA fundamentals help investors to digest information that contributes to Hofseth Biocare's financial success or failures. It also enables traders to predict the movement of Hofseth Stock. The fundamental analysis module provides a way to measure Hofseth Biocare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hofseth Biocare stock.
Hofseth |
Hofseth Biocare ASA Company Price To Sales Analysis
Hofseth Biocare's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Hofseth Biocare Price To Sales | 8.29 X |
Most of Hofseth Biocare's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hofseth Biocare ASA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Hofseth Biocare ASA has a Price To Sales of 8.2921 times. This is 61.25% lower than that of the Healthcare sector and 91.57% lower than that of the Biotechnology industry. The price to sales for all Norway stocks is 27.39% higher than that of the company.
Hofseth Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hofseth Biocare's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hofseth Biocare could also be used in its relative valuation, which is a method of valuing Hofseth Biocare by comparing valuation metrics of similar companies.Hofseth Biocare is currently under evaluation in price to sales category among its peers.
Hofseth Fundamentals
| Return On Equity | -0.95 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (1.07) % | |||
| Current Valuation | 1.03 B | |||
| Shares Outstanding | 395.08 M | |||
| Shares Owned By Insiders | 52.50 % | |||
| Shares Owned By Institutions | 20.43 % | |||
| Price To Earning | (4.13) X | |||
| Price To Book | 5.19 X | |||
| Price To Sales | 8.29 X | |||
| Revenue | 87.62 M | |||
| Gross Profit | 28.51 M | |||
| EBITDA | (87.72 M) | |||
| Net Income | (126.46 M) | |||
| Cash And Equivalents | 36.52 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 123.31 M | |||
| Debt To Equity | 188.20 % | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | 0.39 X | |||
| Cash Flow From Operations | (61.78 M) | |||
| Earnings Per Share | (0.38) X | |||
| Beta | 0.54 | |||
| Market Capitalization | 1.1 B | |||
| Total Asset | 415.97 M | |||
| Retained Earnings | (105 M) | |||
| Working Capital | (22 M) | |||
| Current Asset | 52 M | |||
| Current Liabilities | 74 M | |||
| Z Score | 4.8 | |||
| Net Asset | 415.97 M |
About Hofseth Biocare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hofseth Biocare ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hofseth Biocare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hofseth Biocare ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Hofseth Stock
Hofseth Biocare financial ratios help investors to determine whether Hofseth Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hofseth with respect to the benefits of owning Hofseth Biocare security.